Collecting and storing umbilical cord blood for transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect blood samples from the umbilical cords of newborns immediately after delivery and store them in the MD Anderson Cord Blood Bank. The collected cord blood may be included in the National Cord Blood Inventory, which supports the collection of cord blood for patients needing bone marrow transplants. The samples will be made available to patients through the National Marrow Donor Program, potentially aiding those without a suitable donor. The collection process is safe and does not pose any risk to the mother or baby.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Pregnant women age 18 or older. Cord blood will not be collected from a minor.
2. Able to give verbal informed consent prior to collection of the cord blood.
3. Able to give written informed consent prior to collection of the cord blood.
4. Willing to provide a personal and family medical history (if available) of herself and the biologic father (if available), prior to or following collection of the cord blood.
5. Willing to consent to testing of her blood and the cord blood for infectious diseases, including human immunodeficiency virus (HIV), human T cell lymphotrophic virus (HTLV), hepatitis B and C, cytomegalovirus (CMV), syphilis (RPR), Trypanosoma cruzi (Chagas) and West Nile Virus (WNV). Incomplete tests or positive infectious disease testing results may result in the cord blood unit being deemed unacceptable for clinical use.
6. Willing to consent to testing the cord blood for HLA type, ABO/RhD type, newborn screening and microbial cultures.

Exclusion Criteria:

N/A

Where it's running

• MD Anderson Cord Blood Bank Collection Sites
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Elizabeth Shpall, MD
• Email: eshpall@mdanderson.org
• Phone: 713-745-2161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

• Population PK-guided ATG Dosing in Haplo-HSCT

  This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07791576

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Personalized ATG dosing in unrelated donor stem cell transplants

  This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07648992

• Hematologic cancer survivors after stem cell transplant try a personalized care plan

  This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT07579065

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.